Akeso, Inc. (($HK:9926)) announced an update on their ongoing clinical study. Akeso, Inc. is conducting a multicenter, open-label, Phase II study ...

Anti-CTLA-4 hopeful cleared for sprint to market after early data show rare tumour shrinkage in hard-to-treat patients.

Replimune Group (($REPL)) announced an update on their ongoing clinical study. Replimune Group is conducting a pivotal Phase 3 clinical study ...

Investigators presented initial results from a phase 3 trial of adjuvant durvalumab plus tremelimumab for resected primary renal cell carcinoma (RCC).

Molecular predictors and mechanisms of immune checkpoint inhibitor-induced myocarditis: A case-control study with translational correlates. Predictive factors for cardiac events following concurrent ...

CStone Pharmaceuticals (CStone, HKEX: 2616),  an innovation-driven biopharmaceutical company focused on the research and ...

26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases Deep and durable responses ...

PRESERVE-003 is evaluating gotistobart vs. docetaxel in patients with squamous non-small cell lung cancer (sqNSCLC) who have progressed on chemotherapy and immune checkpoint therapies Pivotal Stage II ...

On February 28, Amgen, Inc. (“Amgen”) filed three petitions for inter partes review, challenging the validity of all claims in three patents assigned to Bristol-Myers Squibb Co. (“BMS”). The claims of ...